MedPath

Exercise for Anxiety

Not Applicable
Recruiting
Conditions
Anxiety
Interventions
Behavioral: Titration to high intensity exercise (T-HIE)
Behavioral: Low intensity exercise prescription
Registration Number
NCT04638946
Lead Sponsor
NYU Langone Health
Brief Summary

90 sedentary adults with a primary anxiety disorder and high anxiety sensitivity will be randomized to either 8 weeks of 1) low intensity exercise, or 2) flexible titration to high intensity exercise (HIE). Blinded, validated clinician-rated and patient-rated outcomes will be assessed over treatment and at 1- and 3-month follow-up. To better understand what mechanisms influence decisions to exercise in the real-world, we will use of heart rate (HR) as an objective mechanistic target for exercise intensity, examine changes in valuation of exercise through a neuroeconomics task, examine changes in interoceptive sensitivity with a heartbeat detection task, and integrate of ecological momentary assessment (EMA) to measure effects of immediate changes in mood with exercise on anxiety outcomes and adherence.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
90
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Titration to high intensity exerciseTitration to high intensity exercise (T-HIE)-
Low intensity exerciseLow intensity exercise prescription-
Primary Outcome Measures
NameTimeMethod
Change in Anxiety Sensitivity Index-3 (ASI-3) scoreBaseline, Week 8

The ASI-3 is an 18-item measure of fear of anxiety sensations with three subscales (physical, cognitive, social concerns). The total score ranges from 0 (lowest anxiety sensitivity) to 72 (highest anxiety sensitivity).

Change in Clinical Global Impressions/Severity Scale scoreBaseline, Week 8

A validated Clinical Global Impressions/Severity Scale (CGI) anchored for anxiety disorders measures overall functioning and clinical improvement. CGI-S is rated from 1 (least disordered) to 7 (most disordered).Scores of 1 or 2 on the CGI-I at post-treatment will represent significant response.

Secondary Outcome Measures
NameTimeMethod
Work and Social Adjustment Scale (WSAS) ScoreWeek 1, Week 4, Week 8, Week 12, Week 20

5 item self-report scale measing impairment in functioning with total score ranging from 0 (no impairment) to 40 (severe impairment).

7 Day Physical Activity Recall Questionnaire (PAR) ScoreWeekly from Week 0 (screening) to Week 20

interviewer-administered measure of self-reported weekly physical activity

Preferences for and Tolerance of the Intensity of Exercise Questionnaire (PRETIE-Q) ScoreWeek 1, Week 4, Week 8, Week 12, Week 20

16-item measure assessing preferences for different exercise intensities, with strong ability to differentiate preferences for HIE vs. LIE.

Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A) ScoreWeek 1, Week 4, Week 8, Week 12, Week 20

14-item clinician-rated measure of severity of anxiety symptoms; The total score ranges from 0 (least severe anxiety symptoms) to 56 (most severe anxiety symptoms).

Barriers Specific-Self-Efficacy Scale (BARSE) ScoreWeek 1, Week 4, Week 8, Week 12, Week 20

13-item measure, will assess barriers to exercise and will be used as a covariate predicting exercise engagement

EngagementWeek 12, Week 20

Completion of exercise of any intensity (proportion of 75min assigned)

AdherenceWeek 8, Week 12, Week 20

Percentage of duration goals achieving target heart rate

Multidimensional Assessment of Interoceptive Awareness (MAIA-2) ScoreWeek 1, Week 4, Week 8, Week 12, Week 20

A 37-item measure with 8 subscales assessing noticing bodily sensations, not distracting from bodily sensations, not worry about bodily sensations, attention regulation, emotional awareness (awareness of connection between emotions and bodily sensations), self-regulation of distress by body sensations, body listening, and trusting one's body.

Ecological Momentary Assessment (EMA) ScoreWeekly from week 1 to week 20

Surveys will consist of five 0-100 Likert scale items assessing mood, anxiety, motivation, energy, and enjoyment.

Overall Anxiety Severity and Impairment Scale (OASIS) ScoreWeek 1, Week 4, Week 8, Week 12, Week 20

A 5-item self-report scale measuring anxiety symptom severity and impairment due to anxiety; response items are coded from 0 to 4 and can be summed to obtain a total score range from 0 (least severity and impairment) to 20 (most severity and impairment).

Score on Montgomery-Asberg Depression Rating Scale (MADRS)Week 1, Week 4, Week 8, Week 12, Week 20

A 10-item clinician-rated measure of depression severity. Total score ranges from 0 (normal/no symptoms) to 60 (severe depression).

Physical Activity Enjoyment Scale (PACES)Week 1, Week 4, Week 8, Week 12, Week 20

18-item measure assessing enjoyment of exercise

HeartrateWeekly from week 1 to week 20

Measured by the Fitbit Charge 3

Neuroeconomics willingness-to-pay (WTP) auction task adapted for exerciseWeek 1, Week 4, Week 8, Week 12, Week 20

will evaluate the subjective threshold between an option's anticipated value and its cost (maximum amount WTP for an expected outcome) and is based on the Becker-DeGroot-Marschak (BDM) auction task68, modified for exercise. Participants will have the opportunity to avoid exercising for a specific timeframe (e.g., 1min, 15min) at a specific intensity (low, moderate, high). The task will first be administered on paper (21-item questionnaire), which will be computerized in line with training aims.

Heartrate by Heartbeat Detection TaskWeek 1, Week 4, Week 8, Week 12, Week 20

Participants silently count their heartbeats for 6 trials of approximately 20-30 seconds (\~5 minutes) while being monitored on an EKG to assess accuracy of reporting. This will assess interoceptive accuracy and will be used as a covariate at baseline and change with intervention will be assessed over time.

Trial Locations

Locations (1)

NYU Langone Health

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath